Cyramza 2021 U.S. PROMOTIONAL AUDIT REPORT

Published July 2022 • 30 Pages

The 5 Key Questions Addressed by this Report:

• How many physicians were reached by Cyramza through reportable promotional activity in 2021 and how does this compare to its peer set in the Colorectal Cancer, Gastric Cancer, Hepatocellular Carcinoma, and Non-Small Cell Lung Cancer markets?
• What promotional mix was leveraged (e.g., sales rep detailing, physician education, and paid speaking) and what was the median spend on each type of activity?
• How does Eli Lilly’s depth of coverage vary within key specialties (e.g., Hematology/Oncology, Nursing, Medical Oncology, Physician Assistant, Radiation Oncology, and Internal Medicine) and how does this compare to its peers and the overall set of rep-accessible physicians?
• How often are physicians receiving paid meals for Cyramza throughout the year (e.g., monthly, quarterly, annually)?
• Who were the most frequent meal recipients and top paid speakers for Cyramza in 2021?

Data Sources and Methodology:

• MDDetails leverages company-reported financial transaction data disclosed through CMS Open Payments. This data set captures all transfers of value (e.g., speaking fees, consulting fees, travel, education, and meals) made on behalf of a drug or device manufacturer to a physician. Currently, over 5 years of longitudinal data is available – covering payments to more than 1,000,000 U.S. healthcare professionals.
• Over 4,900 paid interactions across 2,240 physicians made on behalf of Cyramza were carefully examined to support our analysis. In addition, interaction data from 27 peer products (e.g. Alecensa, Alunbrig, Braftovi, Enhertu, Erbitux, Exkivity, Gilotrif, Imfinzi, Kanjinti, Keytruda, Libtayo, Lonsurf, Lorbrena, Lumakras, Mvasi, Ontruzant, Opdivo, Photofrin, Rybrevant, Stivarga, Tabrecta, Tagrisso, Tecentriq, Tepmetko, Trazimera, Xalkori, and Zirabev ) was leveraged to provide benchmarking and market insights.